Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Restores Alveolar and Pulmonary Vascular Development in a Rat Model of Bronchopulmonary Dysplasia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We tested whether rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-γ agonist, can restore alveolar development and vascular growth in a rat model of bronchopulmonary dysplasia (BPD). Materials and Methods: A rat model of BPD was induced through intra-amniotic delivery of lipopolysaccharide (LPS) and postnatal hyperoxia (80% for 7 days). RGZ (3 mg/kg/d, i.p.) or vehicle was given daily to rat pups for 14 days. This model included four experimental groups: No BPD+vehicle (V), No BPD+RGZ, BPD+V, and BPD+RGZ. On D14, alveolarization, lung vascular density, and right ventricular hypertrophy (RVH) were evaluated. Results: Morphometric analysis revealed that the BPD+RGZ group had significantly smaller and more complex airspaces and larger alveolar surface area than the BPD+V group. The BPD+RGZ group had significantly greater pulmonary vascular density than the BPD+V group. Western blot analysis revealed that significantly decreased levels of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 by the combined exposure to intra-amniotic LPS and postnatal hyperoxia were restored by the RGZ treatment. RVH was significantly lesser in the BPD+RGZ group than in the BPD+V group. Conclusion: These results suggest that RGZ can restore alveolar and pulmonary vascular development and lessen pulmonary hypertension in a rat model of BPD.
Abstract
Purpose: We tested whether rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-γ agonist, can restore alveolar development and vascular growth in a rat model of bronchopulmonary dysplasia (BPD). Materials and Methods: A rat model of BPD was induced through intra-amniotic delivery of lipopolysaccharide (LPS) and postnatal hyperoxia (80% for 7 days). RGZ (3 mg/kg/d, i.p.) or vehicle was given daily to rat pups for 14 days. This model included four experimental groups: No BPD+vehicle (V), No BPD+RGZ, BPD+V, and BPD+RGZ. On D14, alveolarization, lung vascular density, and right ventricular hypertrophy (RVH) were evaluated. Results: Morphometric analysis revealed that the BPD+RGZ group had significantly smaller and more complex airspaces and larger alveolar surface area than the BPD+V group. The BPD+RGZ group had significantly greater pulmonary vascular density than the BPD+V group. Western blot analysis revealed that significantly decreased levels of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 by the combined exposure to intra-amniotic LPS and postnatal hyperoxia were restored by the RGZ treatment. RVH was significantly lesser in the BPD+RGZ group than in the BPD+V group. Conclusion: These results suggest that RGZ can restore alveolar and pulmonary vascular development and lessen pulmonary hypertension in a rat model of BPD.
참고문헌 (34)
- Philip AG, "Bronchopulmonary dysplasia: then and now", Neonatology, 102, pp.1~8 (2012)
- Hartling L, "Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis", Arch Dis Child Fetal Neonatal Ed, 97, pp.F8~F17 (2012)
- Saugstad OD, "Oxygen and oxidative stress in bronchopulmonary dysplasia", J Perinat Med, 38, pp.571~577 (2010)
- Speer CP, "Inflammation and bronchopulmonary dysplasia: a continuing story", Semin Fetal Neonatal Med, 11, pp.354~362 (2006)
- Torday JS, "The evolutionary continuum from lung development to homeostasis and repair", Am J Physiol Lung Cell Mol Physiol, 292, pp.L608~L611 (2007)
- McGowan SE, "The pulmonary lipofibroblast (lipid interstitial cell) and its contributions to alveolar development", Annu Rev Physiol, 59, pp.43~62 (1997)
- Rehan VK, "Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo", Pediatr Pulmonol, 41, pp.558~569 (2006)
- Dasgupta C, "Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazone", Am J Physiol Lung Cell Mol Physiol, 296, pp.L1031~L1041 (2009)
- Wang Y, "Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model", Pediatr Res, 65, pp.150~155 (2009)
- 이현주, "Effects of Postnatal Dexamethasone or Hydrocortisone in a Rat Model of Antenatal Lipopolysaccharide and Neonatal Hyperoxia Exposure", Journal of Korean Medical Science, 27(4), pp.395~401 (2012), 대한의학회[DOI]
- Choi CW, "Bronchopulmonary dysplasia in a rat model induced by intra-amniotic inflammation and postnatal hyperoxia: Morphometric aspects", Pediatric Research, 65(3), pp.323~327 (2009), Lippincott Williams & Wilkins Ltd.
- Fulton RM, "Ventricular weight in cardiac hypertrophy", Br Heart J, 14, pp.413~420 (1952)
- Lee HJ, "Serial changes of lung morphology and biochemical profiles in a rat model of bronchopulmonary dysplasia induced by intra-amniotic lipopolysaccharide and postnatal hyperoxia", JOURNAL OF PERINATAL MEDICINE, 38(6), pp.675~681 (2010), WALTER DE GRUYTER CO
- Kim DH, "Association of Increased Pulmonary Interleukin-6 with the Priming Effect of Intra-Amniotic Lipopolysaccharide on Hyperoxic Lung Injury in a Rat Model of Bronchopulmonary Dysplasia", NEONATOLOGY, 98(1), pp.23~32 (2010), KARGER
- Stenmark KR, "Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia", Annu Rev Physiol, 67, pp.623~661 (2005)
- Hosford GE, "Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung", Am J Physiol Lung Cell Mol Physiol, 285, pp.L161~L168 (2003)
- Kunig AM, "Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia", Am J Physiol Lung Cell Mol Physiol, 291, pp.L1068~L1078 (2006)
- Park HS, "Sildenafil Alleviates Bronchopulmonary Dysplasia in Neonatal Rats by Activating the Hypoxia-Inducible Factor Signaling Pathway", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 48(1), pp.105~113 (2013), AMER THORACIC SOC
- Biscetti F, "Peroxisome proliferator-activated receptors and angiogenesis", Nutr Metab Cardiovasc Dis, 19, pp.751~759 (2009)
- Maniscalco WM, "Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons", Am J Physiol Lung Cell Mol Physiol, 282, pp.L811~L823 (2002)
- Thébaud B, "Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization", Circulation, 112, pp.2477~2486 (2005)
- Bhatt AJ, "Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia", Am J Respir Crit Care Med, 164(10 Pt 1), pp.1971~1980 (2001)
- Thébaud B, "Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease", Am J Respir Crit Care Med, 175, pp.978~985 (2007)
- Vamecq J, "Medical significance of peroxisome proliferator-activated receptors", Lancet, 354, pp.141~148 (1999)
- Yamakawa K, "Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells", Biochem Biophys Res Commun, 271, pp.571~574 (2000)
- Rehan VK, "PPARγ Signaling Mediates the Evolution, Development, Homeostasis, and Repair of the Lung", PPAR Res, 2012, pp.289867~ (2012)
- Torday JS, "The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro", Pediatr Pathol Mol Med, 22, pp.189~207 (2003)
- Torday JS, "Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin", Am J Physiol Lung Cell Mol Physiol, 283, pp.L130~L135 (2002)
- Rehan VK, "Mechanism of reduced lung injury by high-frequency nasal ventilation in a preterm lamb model of neonatal chronic lung disease", Pediatr Res, 70, pp.462~466 (2011)
- Ricote M, "The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation", Nature, 391, pp.79~82 (1998)
- Corton JC, "Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators", Annu Rev Pharmacol Toxicol, 40, pp.491~518 (2000)
- Escher P, "Peroxisome proliferator-activated receptors: insight into multiple cellular functions", Mutat Res, 448, pp.121~138 (2000)
- Cuzzocrea S, "Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation", Eur J Pharmacol, 483, pp.79~93 (2004)
- Rehan VK, "A paradoxical temporal response of the PTHrP", PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung, 2007, pp.293, L182~L190
